La Jolla’s Sanford Consortium for Regenerative Medicine and Osaka, Japan’s Takeda Pharmaceutical Company Ltd. have agreed to establish a $10 million, five-year pact that would advance each organization’s research missions, with the goal of delivering innovative therapeutic products to patients.
“UC San Diego and Takeda share a common goal of disseminating discoveries to improve lives,” said UCSD Chancellor Pradeep Khosla. “By sharing our talent and resources, our alliance will propel our research and delivery and ultimately increase our positive impact on our society.”
The Sanford Consortium is a nonprofit organization — comprising UCSD, the Scripps Research Institute, the Sanford-Burnham Medical Research Institute, the Salk Institute for Biological Studies and the La Jolla Institute for Allergy and Immunology — principally engaged in translational research in stem-cell-based and regenerative medicine.
Takeda is a multinational company with research capabilities and expertise in the development and commercialization of pharmaceutical products.